文献速递腹部技术与安全CTPET

荷兰医疗体系中结直肠癌肝转移患者热消融术后随访中[18F]FDG PET/CT的成本效果

Cost-effectiveness of [18F]FDG PET/CT in follow-up after thermal ablation in patients with colorectal liver metastases in the Dutch healthcare setting.
PubMed 文献 · Eur J Radiol · 2025-07-02

该研究用模拟模型评估荷兰结直肠癌肝转移患者热消融术后3-4个月追加一次[18F]FDG PET/CT的成本效果,结果显示健康获益可忽略(增量QALY<0.001),费用增加1277欧元,主要因额外影像检查,仅<5%模拟患者治疗计划受影响,作者认为追加[18F]FDG PET/CT不太可能具有成本效果。

要点

  • 在标准随访(每3个月血清CEA+增强CT)基础上,热消融术后3-4个月追加一次[18F]FDG PET/CT,增量QALY<0.001。
  • 追加[18F]FDG PET/CT使费用增加1277欧元,主要来自额外影像检查。
  • 仅<5%的模拟患者因[18F]FDG PET/CT改变了治疗计划,可解释健康获益甚微。

核心结论

  • 热消融术后3-4个月追加[18F]FDG PET/CT不太可能具有成本效果。
  • 需要更多研究来确定在患者亚组中或选择其他时间点使用[18F]FDG PET/CT是否具有成本效果。
  • 这需要在多个中心收集更多(更广泛)的随访数据,以反映医院间临床实践的异质性。

研究设计与样本

  • 研究类型为模拟模型分析,模拟荷兰队列的终生健康与成本结局。
  • 评估在标准监测方案(每3个月血清CEA和增强CT)基础上追加一次[18F]FDG PET/CT的成本效果。
  • 标准方案包含热消融术后3-4个月行[18F]FDG PET/CT,治疗可在照护路径下游重复。
  • 生活质量与生存估计基于疾病分期和年龄,成本从医疗保健视角纳入诊断和治疗相关费用。
  • 遵循卫生经济评价报告标准(CHEERS)。

诊断标准与关键数值

  • 追加[18F]FDG PET/CT的增量QALY<0.001,费用增加1277欧元。
  • 仅<5%的模拟患者中[18F]FDG PET/CT影响了治疗计划。

局限性

  • 缺乏提供[18F]FDG PET/CT长期获益数据的研究。
  • 需要收集更多(更广泛)的随访数据,并需在多个中心开展以反映医院间临床实践的异质性。
  • 作者指出需进一步研究以确定患者亚组或替代时间点是否具有成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

INTRODUCTION: The ESMO and ECIO-ESOI consensus guidelines vary in their recommendations regarding the use of 18F-Fluorodeoxyglucose ([18F]FDG) PET/CT in the follow-up after thermal ablation in patients with colorectal liver metastases. This is partly because studies providing data on long-term benefits of [18F]FDG PET/CT are lacking. Therefore, a simulation model was developed to examine how follow-up with [18F]FDG PET/CT impacts treatment planning, health and cost outcomes.

METHODS: For an illustrative Dutch cohort, lifetime health and cost outcomes were simulated to assess the cost-effectiveness of performing a single additional [18F]FDG PET/CT. Patients followed a standard surveillance schedule consisting of three-monthly serum CEA and contrast-enhanced CT, plus [18F]FDG PET/CT 3-4 months after thermal ablation. Therapy could be repeated downstream the care pathway. Quality-of-life and survival estimates were based on disease stage and age. Costs were determined from a healthcare perspective incorporating costs related to diagnostics and treatments. The Consolidated Health Economic Evaluation Reporting Standards were followed.

RESULTS: Health benefits of additional [18F]FDG PET/CT were negligible, incremental QALYs < 0.001, whereas costs increased by €1,277, mainly due to the additional imaging. This lack of health benefits can be explained by the small subset of simulated patients (<5 %) in whom [18F]FDG PET/CT affected treatment planning.

DISCUSSION: Additional [18F]FDG PET/CT 3-4 months after thermal ablation is unlikely to be cost-effective. More research is needed to determine if using [18F]FDG PET/CT in subgroups of patients, or at alternative time points, is cost-effective. This requires collecting more (extensive) follow-up data across multiple centres to reflect heterogeneity between hospitals' clinical practices.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. van Mossel S, Bijlstra OD, van Delft FA, et al. Cost-effectiveness of [18F]FDG PET/CT in follow-up after thermal ablation in patients with colorectal liver metastases in the Dutch healthcare setting. Eur J Radiol. 2025. PMID: 40628067. doi:10.1016/j.ejrad.2025.112277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。